Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Clark Kenneth A	2. Issuer Name and Ticker or Trading Symbol PHARMACYCLICS INC [ PCYC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE	3. Date of Earliest Transaction (MM/DD/YYYY) 5/26/2015
(Street) SUNNYVALE, CA 94085 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$49.00	5/26/2015		D			15000	⁽¹⁾	11/9/2022	Common Stock	15000	⁽¹⁾	0	D
Stock Option (Right to Buy)	$61.44	5/26/2015		D			134	⁽¹⁾	1/2/2023	Common Stock	134	⁽¹⁾	0	D
Stock Option (Right to Buy)	$79.67	5/26/2015		D			280	⁽¹⁾	4/1/2023	Common Stock	280	⁽¹⁾	0	D
Stock Option (Right to Buy)	$74.48	5/26/2015		D			3750	⁽¹⁾	5/9/2023	Common Stock	3750	⁽¹⁾	0	D
Stock Option (Right to Buy)	$85.39	5/26/2015		D			245	⁽¹⁾	7/1/2023	Common Stock	245	⁽¹⁾	0	D
Stock Option (Right to Buy)	$139.89	5/26/2015		D			159	⁽¹⁾	10/1/2023	Common Stock	159	⁽¹⁾	0	D
Stock Option (Right to Buy)	$108.44	5/26/2015		D			192	⁽¹⁾	1/2/2024	Common Stock	192	⁽¹⁾	0	D
Stock Option (Right to Buy)	$107.42	5/26/2015		D			194	⁽¹⁾	4/1/2024	Common Stock	194	⁽¹⁾	0	D
Stock Option (Right to Buy)	$95.08	5/26/2015		D			3750	⁽¹⁾	5/9/2024	Common Stock	3750	⁽¹⁾	0	D
Stock Option (Right to Buy)	$89.58	5/26/2015		D			367	⁽¹⁾	7/1/2024	Common Stock	367	⁽¹⁾	0	D
Stock Option (Right to Buy)	$115.80	5/26/2015		D			284	⁽¹⁾	10/1/2024	Common Stock	284	⁽¹⁾	0	D
Stock Option (Right to Buy)	$124.46	5/26/2015		D			264	⁽¹⁾	1/2/2025	Common Stock	264	⁽¹⁾	0	D

Explanation of Responses:

( 1)

Pursuant to terms of the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie this option was cancelled in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Clark Kenneth A C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVE SUNNYVALE, CA 94085	X

Signatures
/s/ Kenneth A. Clark		5/27/2015
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.